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Abstract: Among the heterocyclic compounds, 8-aminoquinoline and its derivatives have become important candidates for the preparation of 
new antiproliferative metallo-drugs. Here, we reported the synthesis and cytotoxicity evaluation of a series of platinum complexes using 8-
aminoquinoline and its chiral 5,6,7,8-tetrahydro-derivatives as chelating ligands. In the proposed complexes, a differently and opportunely 
alkylated imidazole was used to prepare the corresponding monofunctional platinum complexes. The preliminary cytotoxicity evaluation was 
carried out on the highly aggressive MDA-MB-231, invasive and poorly differentiated triple-negative breast cancer (TNBC) cell line, furnishing 
a significant IC50 10.9±1.3 µM for Pt-IV. This series of complexes revealed an induction of p53, interfering with the progression of the G0/G1 
phase of the cell cycle. 
Introduction 
8-aminoquinoline and its derivatives are heterocyclic compounds that are drawing attention in the field of coordination chemistry due 
to their metal-binding ability along with a variety of biological effects.[1] Known for their recognised antimalarial properties, 8-
aminoquinoline analogues such as sitamaquine and NPC1161 are currently investigated for their antileishmanial and antitrypanosomal 
activities.[2] More recently, an increasing number of 8-aminoquinoline related compounds have been investigated as anticancer agents 
for their ability to trigger different antiproliferative effects such as the inhibition of tyrosine kinases, tubulin polymerization, topoisomerase 
and DNA mechanisms of repair.[3] From a structural point of view, the presence of two nitrogen donor atoms make them bidentate 
chelating ligands able to form thermodynamically stable coordinative complexes with metal ions providing them with novel biochemical 
properties.[4] Thus, 8-aminoquinolines are beheld as a privileged framework for the preparation of new metallodrug candidates. A recent 
paper[5] reported the use of N-(quinoline-8-yl)quinolin-8-sulfonamide as ligand for the synthesis of a copper (II) complex endowed with 
intercalation properties and the ability to trigger DNA fragmentation and apoptosis in Jurkat T cells. [6]  Additionally, a series of transition 
metal complexes of mixed ligands 8-aminoquine-5-substituted uracil bases have been investigated for their cytotoxicity showing a 
significant activity against MOLT-3 cancer cells.[7] Based on these premises and considering that the anticancer potential of platinum 
(II) 8-aminoquinolines complexes has been poorly explored, 8-aminoquinoline scaffold has been selected for the preparation of 
monofunctional platinum complexes.[8] This class of anticancer agents, bearing just one substitution-labile ligand, has recently emerged 
for their unconventional mechanisms of action compared to cisplatin-like drugs, their potent cytotoxic activity and their distinctive 
anticancer spectrum of action. Although there is a certain interaction with DNA double helix, cationic platinum complexes stood out for 
their ability to affect different cell targets becoming a potential tool for the treatment of aggressive and/or orphan cancers. Moreover, 
the cellular uptake of the cationic monofunctional platinum complexes by the organic cation transporters (OCTs) could provide an 
opportunity for a selective delivery to tumours known for overexpressing these channels, such as the human colorectal cancer. [9]  
Our research group have recently reported a series of cationic platinum complexes obtained by the addition of an alkylated imidazole 
ligand to the dichloride neutral precursor led to charged platinum compounds. This series showed a novel cytotoxic profile involving 
mechanisms of action not related to a simple DNA crosslinking as established for cisplatin. The so-synthesised cationic platinum 
compounds displayed a potent anticancer effect on different cancer cell lines known for their poor sensitivity to cisplatin 
chemotherapy.[10]  
In the present study, we reported the synthesis and cytotoxicity evaluation of a series of platinum complexes using 8-aminoquinoline 
and its chiral 5,6,7,8-tetrahydro-derivatives[11] as chelating ligands and in which different alkylated imidazoles were used to prepare the 
corresponding monofunctional platinum complexes. 
Results and Discussion 
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In previous works, two different series of platinum compounds bearing N-alkyl aminomethyl-imidazole ligands were synthetized. Both 
the series, dichloride and cationic ones, were evaluated for their in vitro cytotoxic activity, with the cationic compounds having the best 
results in terms of cytotoxicity. [4a, 10a, 12]  Considering the favourable introduction of a differently substituted alkyl-imidazole as additional 
monocoordinated ligand to form the monofunctional cationic platinum (II) complexes, the choice to conserve this moiety and instead to 
modify the bidentate ligands was applied, with the aim to verify the effect of the bidentate ligands on the biological activity. The synthesis 
of platinum compounds, bearing the commercially available 8-aminoquinoline L1 as ligand, proceeded as reported in Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Synthesis of Pt I-IV. Reagents and Conditions: i) K2PtCl4, H2O, reflux for 18 h; ii) Alkyl-imidazole, DMF, 55°C 18 h. 
The complexes were fully characterized by 1H-NMR, 13C-NMR, 195Pt-NMR, elemental analysis and ESI-MS. With the aim to verify the 
correct conformation of the complexes, and considering that only one stereoisomer was formed during the synthesis, as evinced by 
NMR spectroscopy and by RP-HPLC, 2D-NMR experiment (NOESY) was performed for complex Pt-IV. (spectrum reported in SI) The 
presence of the only one cross-peak between the H in 2 position and H in 3 position on pyridine ring confirmed that the imidazole 
moiety was stereoselectively coordinated in trans to the nitrogen of pyridine as designed for all the complexes in the Figure 1. 
Considering the possibility to selectively reduce the aromatic ring of the pyridine or the phenolic one, ligands L2, L3 and L4 were 
synthetized. In particular, the ligands L3 and L4, being respectively the S and R enantiomers of a tetrahydroquinoline, called CAMPY, 
were resolved and synthetized as previously reported.[11] (Figure 2) The corresponding platinum compounds Pt-VI-XI, were fully 
characterized as for Pt-I-IV and the chemical structures were again confirmed by NOESY experiments. 
The determination of log Pow was evaluated for all the platinum complexes by RP-HPLC, equipped with C18 ODS at 25 °C with 
water/methanol in ratio 80/20 in presence of HCOOH 15 mM as eluent, and using commercially available platinum complexes as 
references.[13] The values were generally comparable, in a range of 0.65-1.51, depending on the type of the aromaticity of the bidentate 
ligands and on the length of the alkyl chain on imidazole monodentate ligand. 
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Figure 2. Synthesis of Pt-V-XI. Reagents and Conditions: i) PtO2 10%, H2 (5 atm), CF3CCOH, 4h; ii) MsCl, DMAP, CH2Cl2, DMSO, 18 h; iii) Pd/C 5%, H2 (10 atm), 
MeOH, 4h; iv) K2PtCl4, H2O, reflux for 18 h; v) PtO2 5%, H2 (5 atm), CF3CCOH, 4h; vi) vinyl acetate, Cal. B Lipase, mol. sieves 4 Å , diisopropyl ether, 60°C, 30h; 
vii) K2CO3, MeOH, reflux, 2h; viii) Alkyl-imidazole, DMF, 55°C 18 h.  
The cytotoxicity of platinum (II) complexes on triple negative breast cancer MDA-MB-231 cell line was tested in vitro by sulforhodamine 
B (SRB) assay. After 48 h incubation with increasing concentration of the compounds, the IC50 values were determined. As shown in 
Table 1, all the complexes significantly reduced, by more than 50%, the cell viability with IC50 values ranging from 4.5±0.5 µM (Pt-I)[14] 
up to 195.8±27.9 µM (Pt-VII). Importantly, the cytotoxic effects of the most active compounds, were confirmed by MTT assay (Table 
1). 
Table 1. Cytotoxic effects of tested platinum (II) complexes on MDA-MB-231. 
Complex 
LogP 
(RP-HPLC) 
IC50 
(SRB assay) 
MDA-MB-231 
IC50 
(MTT assay) 
MDA-MB-231 
IC50 
(SRB assay) 
A2780 
Cisplatin -2.21[15] 59.4 ± 10.06  31.5 ± 4.9 
Pt-I 1.51 4.5±0.5 4.4±0.6  
Pt-II 1.18 48.8±0.6   
Pt-III 1.22 22.5±2.0   
Pt-IV 1.38 10.9±1.3 16.6±2.3 6.2±0.2 
Pt-V 1.3 41.0±11.8   
Pt-VI 0.89 123.4±21.3   
Pt-VII 0.88 195.8±27.9   
Pt-VIII 0.97 95.5±13.5 105.0±16.4 17.8±0.7 
Pt-IX 0.65 119.1±20.2   
Pt-X 0.76 94.9±4.8   
Pt-XI 0.98 60.5±7.8 80.0±10.6 16.3±1.5 
 
To extend this observation we investigated the cytotoxic effects of the most promising cationic pyridine complexes, such as Pt-IV, Pt-
VIII and Pt-XI, on A2780 ovarian cell line. As reported in Table 1, Pt-IV appeared to elicit a similar cytotoxic effect on both cell lines, 
while the two enantiomers Pt-VIII and Pt-XI show a more potent cytotoxic effect on A2780 compared to MDA-MB-231, as indicated by 
lower IC50 values. 
To investigate the molecular mechanism of the cytotoxic effect observed with Pt-IV, Pt-VIII and Pt-XI, we performed a cell cycle analysis 
and determined the expression levels of p53 and proliferating cell nuclear antigen (PCNA). Cisplatin was utilized as positive control. 
Pt-VIII and Pt-XI determined a significant accumulation of proliferating MDA-MB-231 cells into G0/G1 cell line with a concomitant 
reduction of G2/M.  
Figure 3. Effect of Pt-VIII and Pt-XI on cell cycle progression of MDA-MB-231 cell line. The cells were incubated for 24 h with indicated concentrations of tested 
compounds, then cell cycle analysis was performed and expression of p53, PCNA, α-tubulin and β-actin were evaluated by western blot analysis. CisPt: cisplatin; 
Cnt: control. 
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This effect is concentration dependent and appears to be different than cisplatin that slightly reduced the percentage of cells in G0/G1. 
By western blot analysis, we observed a drastic reduction of p53 and PCNA levels after incubation of the cells with 100 µM concentration 
of Pt-VIII and Pt-XI. Surprisingly, also the intracellular levels of housekeeping proteins, such as α-tubulin and β-actin, were significantly 
reduced in response to both compounds. These data indicate that the platinum (II) complexes may affect translational processes. 
(Figure 3) 
Similar effect was also observed with the more potent complex, Pt-IV (Figure 4). The accumulation of cells in the G0/G1 phase was 
observed at 10-15 µM and at similar concentration (12.5-25 µM) a significant reduction of p53, PCNA and β-actin were observed. 
 
Figure 4. Effect of Pt-IV on cell cycle progression of MDA-MB-231 cell line. The cells were incubated for 24 h with indicated concentrations of tested compounds, 
then cell cycle analysis was performed and expression of p53, PCNA, α-tubulin and β-actin were evaluated by western blot analysis. CisPt: cisplatin; Cnt: control. 
This observation prompted us to investigate the effect of these complexes on mRNA levels of p53. As expected, cisplatin significantly 
induced p53 mRNA by 3.9±1.3 fold (Figure 5). Both Pt-VIII and Pt-XI showed a similar induction at the same concentration than cisplatin 
(100 µM), 2.7±1.0 and 3.1±0.1 fold, respectively. However, the most impressive induction of p53 mRNA (11.3±1.7 fold) was observed 
in response to 25 µM of Pt-IV. These data suggested that all the complexes induce p53 mRNA and that Pt-IV appears to be the more 
potent and more efficient on this cellular response. The induction of p53 indicate the nuclear DNA as a potential site of action of platinum 
(II) complexes. Thus, the cellular uptake was investigated by monitoring the platinum concentrations by ICP-MS from a total cell extract 
or DNA isolated from MDA-MB-231 incubated for 3 h with complexes and cisplatin as reference drug. 
 
 
 
 
Figure 5. Effect of platinum (II) complexes on p53 expression in MDA-MB-231 cell line. Cells were seeded (250,000/35 mm petri dish) and incubated with DMEM 
supplemented with 10% FCS; 24 h later the medium was replaced with one containing 10% FCS and the reported concentrations of complexes and cisplatin and 
the incubation was continued for a further 24 h. At the end of this incubation period the total RNA was extracted and mRNA p53 expression evaluated by real-time 
PCR reaction and normalized with 18S. *p < 0.05; ***p<0.001. 
Interestingly, all three platinum (II) complexes accumulate at much higher concentration into the cells compared to cisplatin, suggesting 
a more efficient cell membrane permeability (Figure 6A). The intracellular concentration of Pt-IV was 13.7-fold higher than cisplatin, 
although the amount of 195Pt recovered from DNA samples of MDA-MB-231 cell lines exposed for 3 h to these complexes was 
significantly lower than cisplatin (Figure 6B). However, it must be considered that Pt-IV was utilized at four-fold lower concentration 
than cisplatin (25 µM vs 100 µM). Thus, it is tempting to speculate that the amount of Pt-IV that reached the DNA was proportionally 
higher than Pt-VIII and Pt-XI. 
 
Figure 6. DNA-bound and total intracellular concentrations of 195Pt after incubation of MDA-MB-231 cell line with platinum (II) complexes and cisplatin. Cells were 
seeded (250,000/35 mm petri dish) and incubated with DMEM supplemented with 10% FCS; 24 h later the medium was replaced with one containing 10% FCS 
and complexes or cisplatin at 100 µM concentration, except for Pt-IV that was utilized at 25 µM in DNA samples. The incubation was continued for 3 h at 37 °C. At 
the end of this incubation period, the DNA was extracted, and cell homogenates prepared. Total, (A) and DNA-bound (B) 195Pt concentrations were then determined 
by ICP-MS and the values corrected for protein and DNA contents. 
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Conclusions 
In conclusion, the change in diamine ligand (8-aminequinoline vs 2-methyl-aminoimidazole) drastically modified the biological 
performance of the corresponding cationic platinum (II) complexes despite the same alkyl-imidazole moiety. These differences are 
evident not only in their accumulation in different cellular phase but also in the significant effect on mRNA levels of p53, on α-tubulin 
and on β-actin. In particular, these results suggest that Pt-IV is the most potent cytotoxic agent of this series of platinum (II) complexes 
and that it may act by interacting to the nuclear DNA as confirmed by accumulation data (ICP-MS). However, further analyses are 
required to better define its molecular mechanism of action. 
Experimental Section 
All manipulations involving air sensitive materials were carried out in an inert atmosphere glove box or using standard Schlenk line 
techniques, under an atmosphere of nitrogen or argon in oven-dried glassware. All solvents were used anhydrous. 1H-NMR, 13C-NMR 
and 195Pt-NMR spectra were recorded on a Bruker DRX Avance 300 MHz equipped with a non-reverse probe (BBI) and also on a 
Bruker DRX Avance 600 MHz using as external reference K2PtCl4. MS analyses were performed by using a Thermo Finnigan (MA, 
USA) LCQ Advantage system MS spectrometer with an electrospray ionisation source and an ‘Ion Trap’ mass analyser. The MS spectra 
were obtained by direct infusion of a sample solution in MeOH under ionisation, ESI positive. Elemental analyses were performed using 
a Perkin Elmer SeriesII/CHNS/O 2400 Analyzer. Log Pow’s values and purity were evaluated with Partisil C18-ODS reversed-phase 
HPLC column with Merck-Hitachi L-7100 equipped with Detector UV6000LP. ICP-MS data were recorded with BRUKER aurora M90 
ICP-MS (MA, USA). Quinolin-8-amine (L1) is commercially available. (R)- and (S)-5,6,7,8-tetrahydroquinolin-8-amine (L3 and L4 
respectively) were synthesized according to the procedure reported in literature. [11a, 16] 
Synthesis of (L2): To a solution of quinolin-8-amine (1 mmol, 144 mg) and NiCl2 6H2O (0.5 mmol, 138 mg) in methanol (10 mL), NaBH4 
(4mmol, 151 mg) was added portion wise under cooling for 30 minutes, then the stirring was continued for other 30 minutes at room 
temperature. The solvent was removed in vacuo and the crude product was purified by flash chromatography (hexane/ethyl acetate 
7:3) to afford L2 as a yellow oil. After dissolving the oil in acetone, HCl 4 M (2 equiv.) was added and upon layering diethyl ether the 
product was precipitated as a purple solid corresponding to the L2-dichloride salt.  
3.1.1 8-Amino-1,2,3,4-tetrahydroquinoline (L2). Pinkish solid (128 mg, 87% yield). 1H NMR (300 MHz, CDCl3-d) δ 6.53-6.59 (m, 3H), 
3.33 (t, J = 5.4 Hz, 2H), 3.23 (s, 2H), 2.77 (t, J = 6.3 Hz, 2H), 1.92 (q, J = 6.3 Hz, 2H) ppm; 13C NMR (75 MHz, CDCl3-d)  δ 134.59, 
131.50, 126.33, 117.40, 118.33, 113.05, 39.88, 26.23, 23.11; MS (ESI+): m/z 149.22 [M+H]+  
3.2 General procedure for the synthesis of Pt-I, Pt-V, Pt-VI and Pt-VII 
Potassium tetrachloroplatinate (1 mmol) was dissolved in 10 mL of distilled water in a Schlenk tube under nitrogen atmosphere and to 
this 1 mmol of the diamine ligand was added. The mixture was acidified with HCl 6 M (8 equiv.) and heated under reflux overnight. 
After cooling to room temperature, the product was collected as a differently coloured solid, washed extensively with water followed by 
small amounts of diethyl ether and dried under vacuum. 
3.2.1 (8-Aminoquinoline)dichloroplatinum(II) Pt-I: brown solid (87% yield). 1H NMR (300 MHz, DMF-d7) δ 9.67 (dd, J = 5.3, 1.3 Hz, 1H), 
8.94 (dd, J = 8.4, 1.3 Hz, 1H), 8.09 (dd, J = 21.3, 7.5 Hz, 2H), 7.96 – 7.64 (m, 2H), 4.02 (brs, 2H) ppm; 13C NMR (75 MHz, DMF-d7) δ 
149.12, 148.90, 141.99, 138.72, 130.72, 129.11, 128.23, 127.53, 123.74 ppm; 195Pt NMR (300 MHz, DMF-d7) δ −2106 ppm; Elemental 
analysis of C9H8Cl2N2Pt: calcd. C, 26.36; H, 1.97; N, 6.83; found C, 26.87; H, 2.06; N, 6.94; MS (ESI+): m/z 409.23 [M+H]+ 
3.2.2 (8-Amino-1,2,3,4-tetrahydroquinoline)dichloroplatinum(II) Pt-V: brown solid (72% yield). 1H NMR (300 MHz, DMF-d7) δ 8.62 – 
8.28 (m, 1H), 8.16-8.03 (m, 2H), 7.74 – 7.53 (m, 2H), 7.47 (d, J = 6.4 Hz, 1H), 4.67 – 4.20 (m, 1H), 3.46 – 3.23 (m, 3H), 3.24 – 2.95 
(m, 1H), 2.69 – 2.46 (m, 1H), 2.42 – 2.25 (m, 1H) ppm; 13C NMR (75 MHz, DMF-d7) δ 145.52, 141.75, 134.44, 128.23, 128.12, 123.26, 
49.10, 24.49, 22.06 ppm; 195Pt NMR (300 MHz, DMF-d7) δ −2239 ppm; Elemental analysis of C9H11Cl2N2Pt: calcd. C, 26.10; H, 2.92; 
N, 6.76; found C, 26.28; H, 2.99; N, 6.69; MS (ESI+): m/z 412.46 [M+H]+ 
3.2.3 ((R)-8-Amino-5,6,7,8-tetrahydroquinoline)dichloroplatinum(II) Pt-VI: olive green solid (46% yield). 1H NMR (300 MHz, DMF-d7) δ 
9.08 (d, J = 5.3 Hz, 1H), 7.99 (d, J = 7.8 Hz, 1H), 7.59 – 7.28 (m, 1H), 6.52 (brs, 1H), 5.71 (brs, 1H), 4.64 – 4.23 (m, 1H), 2.92– 2.80 
(m, 2H), 2.45– 2.36 (m, 1H), 2.12 – 1.71 (m, 3H) ppm; 13C NMR (75 MHz, DMF-d7) δ 145.91, 139.01, 138.72, 136.57, 124.73, 61.45, 
27.08, 26.90, 21.56 ppm; 195Pt NMR (300 MHz, DMF-d7) δ −2145 ppm; Elemental analysis of C9H12Cl2N2Pt: calcd. C, 26.10; H, 2.92; 
N, 6.76; found C, 26.40; H, 2.97; N, 6.64; MS (ESI+): m/z 413.71 [M]+ 
3.2.4 ((S)-8-Amino-5,6,7,8-tetrahydroquinoline)dichloroplatinum(II) Pt-VII: yellow green solid (48% yield). 1H NMR (300 MHz, DMF-d7) 
δ 9.10 (d, J = 5.3 Hz, 1H), 7.99 (d, J = 7.8 Hz, 1H), 7.57 – 7.26 (m, 1H), 6.54 (brs, 1H), 5.71 (brs, 1H), 4.67 – 4.21 (m, 1H), 2.93– 2.80 
(m, 2H), 2.45– 2.38 (m, 1H), 2.12 – 1.71 (m, 3H) ppm; 13C NMR (75 MHz, DMF-d7) δ 145.92, 139.05, 138.72, 136.59, 124.71, 61.48, 
27.08, 26.93, 21.56 ppm; 195Pt NMR (300 MHz, DMF-d7) δ −2143 ppm; Elemental analysis of C9H12Cl2N2Pt: calcd. C, 26.10; H, 2.92; 
N, 6.76; found C, 26.33; H, 3.01; N, 6.57; MS (ESI+): m/z 377.78 [M-Cl]+ 
3.3 General procedure for the synthesis of Pt-II, Pt-III, Pt-IV, Pt-VIII, Pt-IX, Pt-X and Pt-XI 
To a stirred solution in anhydrous DMF (1 mL) of the selected platinum dichloride complex (Pt-I, Pt-VI or Pt-VII, 1 mmol) the appropriate 
substituted N-alkyl imidazole (0.9 mmol) was added and the reaction mixture was warmed at 55 °C overnight under a nitrogen 
atmosphere. The solvent was then removed in vacuo and the oily residue was dissolved in dry methanol. After filtration of any eventually 
formed precipitate on a Celite pad, the solution was concentrated to give the crude product as an oil that upon washing with diethyl 
ether afforded the desired complex as a differently coloured powder. 
3.3.1 (8-Aminoquinoline)(1-methyl-1H-imidazole)chloroplatinum(II) chloride Pt-II: deep red solid (24% yield). 1H NMR (300 MHz, 
CD3OD-d4) δ 9.50 – 9.45 (d, 1H), 8.86 – 8.79 (m, 1H), 8.36 (t, J = 12.1 Hz, 1H), 8.08 – 7.92 (m, 2H), 7.88 – 7.57 (m, 1H), 7.51 (s, 1H), 
7.40 – 7.35 (m, 1H), 7.33 – 7.29 (m, 1H), 3.89 (s, 3H) ppm; 13C NMR (75 MHz, CD3OD-d4) δ 150.49, 147.58, 140.39, 139.49, 139.15, 
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130.24, 129.23, 128.28, 127.73, 123.68, 123.30, 122.64, 34.22 ppm; 195Pt NMR (300 MHz, CD3OD-d4) δ −2429 ppm; Elemental 
analysis of C13H14Cl2N4Pt: calcd. C, 31.72; H, 2.87; N, 11.38; found C, 32.02; H, 3.01; N, 11.87; MS (ESI+): m/z 420.92 [M-Cl]+ 
3.3.2 (8-Aminoquinoline)(1-buthyl-1H-imidazole)chloroplatinum(II) chloride Pt-III: deep red solid (62% yield). 1H NMR (300 MHz, 
CD3OD-d4) δ 9.49 (d, J = 4.7 Hz, 1H), 8.70 (d, J = 8.2 Hz, 1H), 8.03 – 7.94 (m, 3H), 7.75 – 7.63 (m, 2H), 7.44 (d, 2H), 7.34 (s, 1H), 
4.25–4.11 (m, 2H), 1.89 – 1.80 (m, 2H), 1.48–1.23 (m, 2H), 1.02 – 0.94 (m, 3H) ppm; 13C NMR (75 MHz, CD3OD-d4) δ 150.46, 148.10, 
140.41, 139.48, 139.30, 130.08, 128.76, 127.79, 127.54, 123.28, 122.86, 120.59, 32.34, 19.17, 19.12, 12.42 ppm; 195Pt NMR (300 MHz, 
CD3OD-d4) δ −2348 ppm; Elemental analysis of C16H20Cl2N4Pt: calcd. C, 35.96; H, 3.77; N, 10.49; found C, 36.37; H, 3.98; N, 10.44; 
MS (ESI+): m/z 498.91 [M]+ 
3.3.3 (8-Aminoquinoline)(1-hexyl-1H-imidazole)chloroplatinum(II) chloride Pt-IV: purple solid (59% yield). 1H NMR (300 MHz, CD3OD-
d4) δ 9.49 (d, J = 4.7 Hz, 1H), 8.71 (d, J = 8.3 Hz, 1H), 8.03 – 7.88 (m, 2H), 7.79 – 7.62 (m, 3H), 7.44 (s, 1H), 7.38 (s, 1H), 4.40 – 3.99 
(m, 2H), 1.93 – 1.85 (m, 2H), 1.68 – 1.14 (m, 6H), 1.08 – 0.66 (m, 3H) ppm; 13C NMR (75 MHz, CD3OD-d4) δ 150.44, 148.09, 140.38, 
139.47, 130.21, 130.08, 129.21, 128.77, 128.51, 127.81, 127.54, 122.85, 49.23, 30.93, 29.74, 25.70, 22.13, 12.91 ppm; 195Pt NMR 
(300 MHz, CD3OD-d4) δ −2324 ppm; Elemental analysis of C18H24Cl2N4Pt: calcd. C, 38.44; H, 4.30; N, 9.96; found C, 38.68; H, 4.79; 
N, 10.21; MS (ESI+): m/z 526.95 [M]+ 
3.3.4 ((R)-8-amino-5,6,7,8-tetrahydroquinoline)(1-hexyl-1H-imidazole)chloroplatinum(II) chloride Pt-VIII: brown solid (46% yield). 1H 
NMR (300 MHz, CD3OD-d4) δ 9.04 (d, J = 5.3 Hz, 1H), 8.00 (d, J = 7.4 Hz, 1H), 7.51 (s, 1H), 7.40 – 7.30 (m, 2H), 7.10 (s, 1H), 4.53 – 
4.51 (m, 1H), 4.31 – 3.95 (m, 2H), 3.10 – 2.90 (m, 2H), 2.38 – 2.34 (m, 1H), 2.20 – 1.57 (m, 5H), 1.31 – 1.28 (m, 6H), 0.90 – 0.88 (m, 
3H) ppm; 13C NMR (75 MHz, CD3OD-d4) δ 161.68, 146.17, 140.75, 137.16, 125.03, 124.33, 122.21, 121.30, 60.39, 48.27, 30.83,  30.20, 
29.37, 26.41, 25.64, 22.09, 21.19, 12.86 ppm; 195Pt NMR (300 MHz, CD3OD-d4) δ −2471 ppm; Elemental analysis of C18H28Cl2N4Pt: 
calcd. C, 38.17; H, 4.98; N, 9.89; found C, 38.56; H, 4.78; N, 9.95; MS (ESI+): m/z 530.94 [M]+ 
3.3.5 ((S)-8-Amino-5,6,7,8-tetrahydroquinoline)(1-methyl-1H-imidazole)chloroplatinum(II) chloride Pt-IX: dark-red solid (42% yield). 1H 
NMR (300 MHz, CD3OD-d4) δ 8.32 (s, 1H), 8.00 (d, J = 7.8 Hz, 1H), 7.61 (d, J = 6.20 Hz, 1H), 7.43 – 7.39 (m, 1H), 7.32 (s, 1H), 7.06 
(s, 1H), 4.51 – 4.47 (m, 1H), 3.82 (s, 3H), 2.98 – 2.86 (m, 2H), 2.40 – 2.35 (m, 1H), 2.12 – 2.08 (m, 1H), 1.91 – 1.88 (m, 2H) ppm; 13C 
NMR (75 MHz, CD3OD-d4) δ 161.66, 151.12, 140.81, 138.56, 134.60, 127.83, 125.09, 116.09, 60.34,                                                                                   
47.86, 33,81, 29.39, 21.03; 195Pt NMR (300 MHz, CD3OD-d4) δ −2412 ppm; Elemental analysis of C13H18Cl2N4Pt: calcd. C, 31.46; H, 
3.66; N, 11.29; found C, 31.11; H, 3.97; N, 11.13; MS (ESI+): m/z 424.00 [M-Cl]+ 
3.3.6 ((S)-8-Amino-5,6,7,8-tetrahydroquinolin)(1-buthyl-1H-imidazole)chloroplatinum(II) chloride Pt-X: brown solid (53% yield). 1H 
NMR (300 MHz, CD3OD-d4) δ 9.02 (d, 1H), 8.27 (s, 1H), 8.00 (d, J = 7.3 Hz, 1H), 7.51 (s, 1H), 7.46 – 7.33 (m, 2H), 7.10 (s, 1H), 4.57 
– 4.51 (m, 1H), 4.28 – 4.07 (m, 2H), 3.06 – 2.83 (m, 2H), 2.43 – 2.38 (m, 1H), 2.18 – 1.92  (m, 1H), 1.96 – 1.75 (m, 4H), 1.45 – 1.20 
(m, 2H), 1.06 – 0.84 (m, 3H) ppm; 13C NMR (75 MHz, CD3OD-d4) δ 161.65, 146.23, 140.74, 139.94, 137.14, 128.44, 125.05, 122.19, 
60.39, 47.87, 32.15, 29.37, 26.35, 21.07, 19.10, 12.37 ppm; 195Pt NMR (300 MHz, CD3OD-d4) δ −2468 ppm; Elemental analysis of 
C16H24Cl2N4Pt: calcd. C, 35.70; H, 4.49; N, 10.41; found C, 35.13; H, 4.97; N, 10.57; MS (ESI+): m/z 503.89 [M]+ ; 467.07[M-Cl]+ 
3.3.7 ((S)-8-amino-5,6,7,8-tetrahydroquinoline)(1-hexyl-1H-imidazole)chloroplatinum(II) chloride Pt-XI: brown solid (58% yield). 1H 
NMR (300 MHz, CD3OD-d4) δ 9.03 (d, 1H), 8.03 (d, J = 7.4 Hz, 1H), 7.52 (s, 1H), 7.42 – 7.33 (m, 2H), 7.09 (s, 1H), 4.57 – 4.50 (m, 
1H), 4.24 – 4.04 (m, 2H), 3.07 – 2.78 (m, 2H), 2.43 – 2.39 (m, 1H), 2.22 – 1.65 (m, 5H), 1.38 – 1.25 (m, 6H), 0.92 – 0.83 (m, 3H) ppm; 
13C NMR (75 MHz, CD3OD-d4) δ 161.63, 146.22, 140.73, 137.13, 125.00, 124.31, 122.25, 121.31, 60.43, 48.23, 30.79,  30.23, 29.33, 
26.45, 25.63, 22.13, 21.16, 12.83 ppm; 195Pt NMR (300 MHz, CD3OD-d4) δ −2473 ppm; Elemental analysis of C18H28Cl2N4Pt: calcd. C, 
38.17; H, 4.98; N, 9.89; found C, 38.53; H, 4.83; N, 9.91; MS (ESI+): m/z 531.00 [M]+ ; 495.12[M-Cl]+ 
3.4 Log Pow determination. RP-HPLC analysis were performed to correlate the hydrophobicity of the platinum (II) complexes with their 
retention time. The chromatograms were registered using Partisil C18-ODS reversed-phase HPLC column, at 25 °C and with 
water/methanol in ratio 80/20 in presence of HCOOH 15 mM as mobile phase and using KI as internal standard (flow rate of 1 mL/min, 
λ= 210 nm). The calibration curve was realized in comparison with reference compounds, chosen in commercially available platinum 
compounds series (i.e. cisplatin, oxaliplatin and carboplatin). 
3.5 Biological evaluation procedures. 
3.5.1 Reagents. Eagle’s minimum essential medium (MEM) was purchased from Sigma Aldrich, while trypsin-EDTA, penicillin, 
streptomycin, sodium pyruvate, non-essential amino acid solution, fetal calf serum (FCS), plates and Petri dishes were purchased from 
EuroClone. The platinum(II) complexes were dissolved in dimethyl sulfoxide (DMSO) before performing each experiment. The maximal 
concentration utilized was 200 µM; cisplatin was tested up to 100 µM. The amount of DMSO did not exceed the 0.25% of the culture 
media volume.  
3.5.2 Cell culture. Human triple negative cancer, MDA-MB-231, and ovarian carcinoma cell line, A2780, were cultured in DMEM 
supplemented with 10% FCS, non-essential amino acids, and penicillin/streptomycin at 37°C in a humidified atmosphere (5% CO2 and 
95% air). 
3.5.3 Cell viability assay. Sulphorhodamine B (SRB) assay was performed to assess the cell viability after treatments. 5x103 cells/well 
were seeded in a 96-well tray in triplicate. After 24h of incubation, the cells were treated with different concentrations of compounds. 
SRB assay were performed after 48h as previously described [17]. The determination of the conversion of MTT (3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) to formazan was determined as previously described [18].  
3.5.4 Retrotranscription and quantitative PCR (RT-qPCR). RNA Preparation and Quantitative Real Time PCR-Total RNA was extracted 
with the iScriptTM RT-qPCR Sample Preparation Buffer (BIO-RAD) cDNA synthesis preparation reagents (Bio-Rad) according to 
manufacturer’s instructions. Reverse transcription-polymerase first-strand cDNA synthesis was performed by using the Maxima First 
Strand cDNA Synthesis Kit (Thermo Scientific) [17]. qPCR was then performed by using the PowerUpTM SYBRTM Green Master Mix 
(Thermo Scientific) and specific primers for the selected genes. The primer sequences used for qPCR analysis were: p53 Forward 5’-
GGAGGTTGTGAGGCGCTGG-3’ Reverse 5’-CACGCACCTCAAAGCTGTTC-3’; 18S Forward 5’-CTCAACACGGGAAACCTCAC-3’ 
Reverse 5’-CGCTCCACCAACTAAGAACG-3’[17]. The analyses were performed with the Mx3000P qPCR System (Agilent), with the 
following cycling conditions: 95°C, 2 min; 95°C, 15 sec and 60°C, 1 min for 40 cycles. Data were expressed as Ct values and used for 
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the relative quantification of targets with the Ct calculation. The Ct were correct by multiplying the ratio value between the efficiency 
of specific primers and housekeeping 18S. The efficiency was calculated as ((10^(-1/slope))-1)*100.  
3.5.5 Western blot analysis. Cells were washed twice with PBS and lysed with a solution of 50 mM Tris pH 7.5, 150 mM NaCl, 0.5% 
Nonidet-P40, containing protease and phosphatase inhibitor cocktails (SIGMA, Milan, Italy) for 30 min. on ice. Twenty µg of proteins 
and a molecular mass marker (Thermo Scientific) were separated on 4–12% SDS-PAGE (BIO-RAD) under denaturing and reducing 
conditions. Proteins were then transferred to a nitrocellulose membrane by using the Trans-Blot® Turbo™ Transfer System (BIO-RAD). 
Membranes were washed with Tris-buffered saline-Tween 20 (TBS-T), and nonspecific binding sites were blocked in TBS-T containing 
5% nonfat dried milk for 60 min at room temperature. Blots were incubated overnight at 4 °C with a diluted solution (5% nonfat dried 
milk) of the following human primary antibodies: anti-p53 (mouse monoclonal antibody, sigma; dilution 1:5000), anti PCNA (mouse 
monoclonal, sigma; dilution 1:1,000), anti-α-tubulin (mouse monoclonal antibody, Sigma clone DM1A; dilution 1:2,000) and anti β-actin 
(mouse monoclonal antibody, Sigma; dilution 1:2,000). Membranes were washed with TBS-T and then exposed for 90 min at room 
temperature to a diluted solution (5% nonfat dried milk) of the secondary antibodies (peroxidase-conjugate goat anti-rabbit, and anti-
mouse, Jackson Immunoresearch). Immunoreactive bands were detected by exposing the membranes to ClarityTM Western ECL 
chemiluminescent substrates (Bio-Rad) for 5 min, and images were acquired with a VersaDoc 4000 Imaging System (Bio-Rad) [19]. 
Densitometric readings were evaluated using the ImageLabTM software as previously described.  
3.5.6 Determination of intracellular and DNA-bound 195Pt concentration. For the determination of total intracellular 195Pt concentrations, 
cells were washed twice with PBS and lysed by incubation with 1% Triton X100/0.1% SDS for 5 min at room temperature. Cell lysates 
were then cleared by centrifugation at 14,000g for 10 min, and the 195Pt concentrations determined by ICP-MS. The data were 
normalized with the protein concentrations determined using the BCA protein assay. For the DNA-bound 195Pt concentrations, the 
nuclear DNA was extracted by incubating cell monolayers with digest buffer (50 mM Tris–HCl 1 M, 100 mM NaCl, 100 mM EDTA, 1% 
SDS) then transferred to 1.5 mL microcentrifuge tubes and saturated NaCl solution added. The samples were then clear by 
centrifugation for 15 min at 13,000 rpm and the supernatant transferred to new microcentrifuge tubes and DNA precipitated by 
isopropanol. DNA was then washed by centrifugation two times with 70% ethanol and resuspended in TE buffer (10 mM Tris pH 8.0; 
0.1 mM EDTA). The 195Pt concentrations were then determined by ICP-MS. 
3.5.7 Statistical analysis. Experimental data are expressed as mean ± SD of at least three independent experiments. The effects of the 
complexes versus control were analyzed by two-tailed Student’s t test for unpaired data. The concentration of compounds required to 
reduce by 50% of cell viability (IC50) was calculated by nonlinear regression curve (GraphPad Prism, Version 5.01). 
Keywords: 8-amino-5,6,7,8-tetrahydroquinoline• Alkyl-imidazole• Cationic platinum (II) complex • Triple negative breast cancer • 
Monofunctional metallo-drugs. 
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